SCHEMBL2736802

SCHEMBL2736802

CCCCn1cc(-c2ccc(Cl)s2)cc(C(=O)NCc2ccc(F)cc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.44
POLB P06746 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CNR2 P34972 9/20 0.42
CNR1 P21554 9/20 0.42
LIPG Q9Y5X9 1/20 0.41
TP53 P04637 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TRPA1 O75762 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736799 0.91 CNR2 (0.52) POLBCNR2CNR1TP53HPGD
SCHEMBL2736820 0.85 CNR1 (0.50) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736858 0.84 ALDH1A1 (0.48) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736792 0.83 CNR2 (0.44) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736808 0.83 CNR1 (0.48) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736854 0.82 CNR1 (0.48) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736889 0.82 PTGER4 (0.44) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736883 0.82 CNR1 (0.50) PDE10APOLBRXFP1CNR2CNR1
SCHEMBL2736801 0.82 CNR2 (0.50) POLBCNR2CNR1TP53NPC1
SCHEMBL2736864 0.81 POLB (0.46) PDE10APOLBRXFP1CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R PDE10A 3728/4885POLB 4136/4885RXFP1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.